Sanaria Inc. and the University of Maryland College Park Awarded Collaborative, US $3M NIH Phase II Small Business Innovation Research Grant

18-Jun-2012 - USA

Sanaria Inc and the Institute for Bioscience and Biotechnology Research (IBBR) of the University of Maryland College Park announce the receipt of a multi-year Phase II Small Business Innovation Research (SBIR) Grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The grant, worth nearly $3 million over a 3 year period, will fund research and development to genetically engineer mosquitoes that produce large numbers of parasites for Sanaria's malaria vaccine manufacturing process. This Phase II SBIR award allows the continuation and expansion of a successful partnership supported by a Phase I SBIR. Malaria vaccine development is a major humanitarian objective. Malaria causes more than 200 million clinical cases and between 650,000 and 1.2 million deaths each year.

Dr. Peter F. Billingsley, Sanaria Senior Scientist and Principal Investigator on the grant states, "Sanaria and IBBR have established a powerful system with which to exploit new techniques in mosquito genetics and efficiently test the ability of modified mosquito strains to sustain high level P. falciparum infections." According to Dr. David O'Brochta, a Principal Investigator on the grant and Director of the Insect Transformation Facility at IBBR, "The partnership between Sanaria and IBBR supported by this grant is an extraordinary opportunity to continue to exploit the unique capabilities of our Insect Transformation Facility in pursuit of a goal of tremendous importance."

https://www.bionity.com/en/news/138379/sanaria-inc-and-the-university-of-maryland-college-park-awarded-collaborative-us-3m-nih-phase-ii-small-business-innovation-research-grant.html